Condition (MeSH)
Toxic Optic Neuropathy
ClinicalTrials.gov lists 3 trials for Toxic Optic Neuropathy or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
3 of the 3 trials are tagged with Toxic Optic Neuropathy itself; the rest are tagged with a narrower condition beneath it.
When did Toxic Optic Neuropathy trials start? (3)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2/3
- Phase 3
- Not applicable
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2020 | 1 |
| 2019 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 3 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Toxic Optic Neuropathy trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Not applicable | 1 |
How many Toxic Optic Neuropathy trials are recruiting? (2)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Completed | 1 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Toxic Optic Neuropathy? (2)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2023 | No |
| Management of toxic optic neuropathy via a combination of Wharton's jelly-derived mesenchymal stem cells with electromagnetic stimulation. | Stem cell research & therapy | 2021 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.